Literature DB >> 15330446

Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models.

W V Kalina1, L J Gershwin.   

Abstract

Respiratory syncytial virus (RSV), an RNA virus in the family Paramyxoviridae, causes respiratory disease in humans. A closely related bovine RSV is responsible for a remarkably similar disease syndrome in young cattle. Severe RSV disease is characterized by bronchiolitis. The impact of RSV on human health is demonstrated annually when infants are admitted to the hospital in large numbers. Nearly every child will have been infected with RSV by the age of 3 years. While the disease is most severe in young infants and elderly people, it can re-infect adults causing mild upper respiratory tract disease throughout life. In addition, there is growing evidence that RSV infection may also predispose some children to the development of asthma. This is based on the observation that children who wheeze with RSV-induced bronchiolitis are more likely to develop into allergic asthmatics. Recent studies describe attempts to create an RSV induced asthma model in mice and other species; these have shown some degree of success. Such reports of case studies and animal models have suggested a wide range of factors possibly contributing to RSV induced asthma, these include timing of RSV infection with respect to allergen exposure, prior allergic sensitization, environmental conditions, exposure to endotoxin, and the genetic background of the person or animal. Herein, we primarily focus on the influence of RSV infection and inhalation of extraneous substances (such as allergens or endotoxin) on development of allergic asthma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330446      PMCID: PMC2270713          DOI: 10.1080/10446670410001722131

Source DB:  PubMed          Journal:  Clin Dev Immunol        ISSN: 1740-2522


  18 in total

1.  The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis.

Authors:  Jiehua Chen; Yu Deng; Jing Zhao; Zhengxiu Luo; Wansheng Peng; Juan Yang; Luo Ren; Lijia Wang; Zhou Fu; Xiqiang Yang; Enmei Liu
Journal:  J Clin Immunol       Date:  2010-05-02       Impact factor: 8.317

2.  Pneumocystis infection in an immunocompetent host can promote collateral sensitization to respiratory antigens.

Authors:  Steve D Swain; Nicole Meissner; Soo Han; Allen Harmsen
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

3.  A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Authors:  Tiffany M Turner; Les P Jones; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

4.  Respiratory Syncytial Virus (RSV) Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology.

Authors:  Anurag Sharma; Wenzhu Wu; Biin Sung; Jing Huang; Tiffany Tsao; Xiangming Li; Rika Gomi; Moriya Tsuji; Stefan Worgall
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

5.  Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.

Authors:  Anurag Sharma; Rebecca Wendland; Biin Sung; Wenzhu Wu; Thomas Grunwald; Stefan Worgall
Journal:  Vaccine       Date:  2014-08-26       Impact factor: 3.641

6.  Identification of gene biomarkers for respiratory syncytial virus infection in a bronchial epithelial cell line.

Authors:  Yuh-Chin T Huang; Zhuowei Li; Xhevahire Hyseni; Michael Schmitt; Robert B Devlin; Edward D Karoly; Joleen M Soukup
Journal:  Genomic Med       Date:  2009-05-15

Review 7.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

Review 8.  Development of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implications.

Authors:  Erwin W Gelfand
Journal:  Curr Opin Immunol       Date:  2012-09-13       Impact factor: 7.486

9.  RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

Authors:  Rene Alvarez; Sayda Elbashir; Todd Borland; Ivanka Toudjarska; Philipp Hadwiger; Mathias John; Ingo Roehl; Svetlana Shulga Morskaya; Rick Martinello; Jeffrey Kahn; Mark Van Ranst; Ralph A Tripp; John P DeVincenzo; Rajendra Pandey; Martin Maier; Lubomir Nechev; Muthiah Manoharan; Victor Kotelianski; Rachel Meyers
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

10.  Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus.

Authors:  Tamaki Okabayashi; Shin-ichi Yokota; Yuko Yoto; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  Clin Vaccine Immunol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.